Top Markets
#1 PulseChain PulseChain +45.01%
#2 SkyAI SkyAI +14.20%
#3 eCash eCash +9.92%
#4 OPENLOOT OPENLOOT +8.47%
#5 Fake World Assets Fake World Assets +8.42%
#6 Ergo Ergo +7.75%
#7 Verus Coin Verus Coin +7.73%
#8 Meteora Meteora +7.31%
#9 Unit Pump Unit Pump +7.21%
#10 Pump.fun Pump.fun +7.21%
Coin of the day
PulseChain PulseChain
Settings
Language
ENGLISH
Currency
USD
Theme
Defence Therapeutics Inc. Defence Therapeutics Inc.

Defence Therapeutics Inc.

DTC
Rank in Stocks #28133
Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a... Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases. A cornerstone of its approach is the exclusive ACCUM™ technology, engineered to precisely and safely transport vaccine antigens or antibody-drug conjugates (ADCs) directly to their intended cellular targets. The company's development efforts span several key areas: novel dendritic cell vaccines for various cancers, protein-based vaccines addressing COVID-19 and other infectious ailments, and specialized antibody-drug conjugate products aimed at different cancer types. Defence Therapeutics Inc. adopted its current name in March 2020, having previously operated as Accum Therapeutics Inc.
Share Price
$0.37430781
Last synced: 2026-08-19
Market Cap
$28.37M
Change (1 day)
2.00%
Change (1 year)
-13.46%
Country
CA
Trade Defence Therapeutics Inc. (DTC)

Category

Healthcare
Revenue for Defence Therapeutics Inc. (DTC)
Revenue in Aug 2026 TTM: 0
According to Defence Therapeutics Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Defence Therapeutics Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH